Published 12 hours ago • loading... • Updated 12 hours ago

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

On Saturday, May 30, 2026, Dizal Pharmaceutical presented new study results for two non-small cell lung cancer treatments at the American Society of Clinical Oncology Annual Meeting.
Patients with EGFR-mutant NSCLC often develop resistance to third-generation EGFR TKI treatments, with EGFR C797X mutations and brain metastases frequently causing disease progression and mortality.
Oral presentation data for the fourth-generation EGFR TKI DZD6008 showed 82.1% of patients experienced tumor shrinkage, with 6-month progression-free survival rates reaching 70.6% and 61.8% for 40 mg and 60 mg cohorts.
The second study showed that golidocitinib, a JAK1-selective inhibitor, demonstrated enhanced anti-tumor responses when combined with an anti-PD-1 antibody as first-line therapy for patients without driver mutations.
CEO Xiaolin Zhang of Dizal stated the company plans to collaborate with investigators globally to accelerate clinical development, addressing unmet medical needs for patients with advanced NSCLC.

Insights by Ground AI

38 Articles

keenesentinel.com

+37 Reposted by 37 other sources

Center

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKIIn treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib, a JAK-only inhibitor, in combination with…

12 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year